XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
The dissolution method you choose at IND is almost never the dissolution method that survives to NDA. The IND method is selected for analytical simplicity. The NDA method is selected for clinical relevance.
View details →
The dissolution specification for an immediate release tablet is fundamentally a quality control tool — it confirms that the tablet disintegrates and releases the drug quickly. The dissolution specification for an extended release tablet
View details → HPMC hydrophilic matrix tablets are the most common controlled release platform in oral solid dosage form development — and the most commonly documented without the scientific argument that FDA chemistry reviewers need to evaluate
View details → For a 5 mg tablet where the API is 2.5% of the tablet weight, blend uniformity is not a process control — it is the single most consequential CQA in the manufacturing process. A
View details → A specification table in 3.2.P.5 is not a list of limits — it is a collection of regulatory arguments, each of which must be defended by data. When FDA chemistry reviewers ask "what is
View details → The 36-month shelf life on your oral tablet is a statistical prediction, not a measured fact — and the quality of that prediction depends entirely on whether the ICH Q1E linear regression model you
View details → Selecting a container closure system for an oral solid dosage form is a stability decision, not a packaging decision. For a moisture-sensitive tablet where degradation accelerates sharply with humidity, ordinary bottle-level moisture ingress over
View details →
Allogeneic cell therapy does what autologous cannot: it makes a single manufacturing batch that can treat hundreds of patients. The CMC infrastructure required to support that model is categorically different.
View details → iPSC-derived cell therapies represent the most ambitious manufacturing challenge in modern medicine. The CMC package required to support a CBER IND for one of these products reflects that ambition — and its complexity.
View details → Tumor-infiltrating lymphocyte and NK cell therapies occupy the frontier of cell therapy CMC. The regulatory expectations are evolving — but CBER's fundamental requirements for potency, identity, and manufacturing consistency are not.
View details → Cell therapy stability studies are not shorter versions of biologics stability programs. They are fundamentally different studies — because cell therapy products degrade through biological processes that conventional stability science was not built to
View details →
Process validation for cell therapy is not impossible — it is just different. The FDA's 2011 guidance applies. But the way you design Stage 1, execute Stage 2, and monitor Stage 3 must reflect
View details → The analytical methods used to characterize and release cell therapy products are unlike any other in pharmaceutical science. Validating them to ICH Q2(R2) requires a cell-therapy-specific strategy that most standard method validation platforms cannot
View details → The QOS for a cell therapy product must summarize a drug that is, by definition, incompletely characterized. The way you handle that reality in Module 2.3 determines whether CBER trusts your entire CMC package.
View details → The cell therapy programs that reach BLA submission on schedule are not the ones that moved fastest in Phase 1. They are the ones that invested in CMC infrastructure while moving through Phase 1.
View details → A cell therapy CMC package built for CBER will satisfy many EMA requirements — and fail specific ones. Discovering which ones at pre-submission costs less than discovering them at Day 180 of a CAT
View details → A cell therapy BLA without a facility that passes inspection is a submission, not an approval. Understanding what CBER inspectors evaluate before you build or validate your facility is the only way to avoid
View details → The most successful cell therapy programs treat BLA approval not as the end of CMC work, but as the beginning of the manufacturing lifecycle where every change requires a regulatory strategy.
View details →